En Carta Diagnostics

En Carta Diagnostics specializes in developing low-cost, high-accuracy paper-based diagnostic tools designed to detect pandemics, epidemics, and bacterial resistance. The company operates in the biotech and smart pharma sectors, serving healthcare providers, laboratories, and medical institutions. En Carta's core technology leverages cell-free systems to create point-of-care nucleic acid diagnostics for diseases such as HIV, TB, and HPV, with precision down to the single nucleotide level and costs below $1. Their business model focuses on rapid development and deployment of diagnostic kits, making money through the sale of these kits and associated technologies. The company aims to bring next-generation medical-grade diagnostics to various settings, ensuring positive outcomes for stakeholders through evidence-based methodologies. En Carta's platform technology has been validated in numerous pathogen tests and field trials, offering results for 100 tests in less than an hour. The company was selected for the innovation accelerator Wilco for the S2022 biotech and smart pharma cohort, highlighting its commitment to innovation and market readiness.

Keywords: paper-based diagnostics, cell-free systems, nucleic acid, point-of-care, HIV, TB, HPV, biotech, smart pharma, innovation.